En undersøgelse af NVL-655 hos patienter med avanceret NSCLC og andre solide tumorer, der rummer ALK-omlejring eller aktiverer ALK-mutation (ALKOVE-1)
Et fase 1/2-studie af den selektive anaplastiske lymfomkinase (ALK)-hæmmer NVL-655 hos patienter med avanceret NSCLC og andre solide tumorer (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.
Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors.
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors.
A drug-drug interaction (DDI) sub-study will determine the effect of neladalkib on the pharmacokinetics of midazolam and repaglinide, as well as the effect of itraconazole on the pharmacokinetics of neladalkib, in patients with advanced ALK-positive NSCLC
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
In Phase 2, study patients will be enrolled into 6 distinct cohorts:
- Cohort 2a: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib, alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
- Cohort 2b: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed.
- Cohort 2c: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is allowed.
- Cohort 2d: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy is allowed.
- Cohort 2e: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts.
- Cohort 2f: Patients with other solid tumors harboring an ALK rearrangement or activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists.
In the DDI sub-study, study patients will be enrolled into 2 distinct cohorts:
- Cohort G (DDI sub-study with midazolam and repaglinide): Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI.
- Cohort H (DDI sub-study with itraconazole): Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Udvidet adgang
Udvidet adgang
Ledig
- Tilgængelig: Udvidet adgang er i øjeblikket tilgængelig for denne forsøgsbehandling, og patienter, der ikke er deltagere i den kliniske undersøgelse, kan muligvis få adgang til lægemidlet, det biologiske eller medicinske udstyr undersøgt.
- Ikke længere tilgængelig: Udvidet adgang var tilgængelig for denne intervention tidligere, men er ikke tilgængelig i øjeblikket og vil ikke være tilgængelig i fremtiden.
- Midlertidigt ikke tilgængelig: Udvidet adgang er i øjeblikket ikke tilgængelig for denne intervention, men forventes at være tilgængelig i fremtiden.
- Godkendt til markedsføring: Interventionen er blevet godkendt af U.S. Food and Drug Administration til brug for offentligheden.
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Nuvalent Clinical Trial
- Telefonnummer: 857-357-7000
- E-mail: clinicaltrials@nuvalent.com
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2065
- Rekruttering
- Royal North Shore Hospital
-
Ledende efterforsker:
- Malinda Itchins, MBBS PhD
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Rekruttering
- Princess Alexandra Hospital
-
Ledende efterforsker:
- Kenneth O'Byrne, MD
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Rekruttering
- Peter MacCallum Cancer Centre
-
Ledende efterforsker:
- Benjamin Solomon, MD, PhD
-
-
-
-
-
Antwerp, Belgien, 2650
- Rekruttering
- Universitair Ziekenhuis Antwerpen (UZA)
-
Ledende efterforsker:
- Reinier Wener, MD
-
Leuven, Belgien, 3000
- Rekruttering
- Universitaire Ziekenhuizen Leuven Campus Gastthuisberg
-
Ledende efterforsker:
- Christophe Dooms, MD
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Rekruttering
- Cross Cancer Institute
-
Ledende efterforsker:
- Quincy Siu Chung Chu, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canada, VZ 4E6
- Rekruttering
- BC Cancer Center
-
Ledende efterforsker:
- Jamie Feng, MD
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Rekruttering
- The Ottawa Hospital Cancer Center
-
Ledende efterforsker:
- Garth Nicholas, MD
-
Toronto, Ontario, Canada, M5G 0A3
- Rekruttering
- Princess Margaret Cancer Centre
-
Ledende efterforsker:
- Geoffrey Liu, M.D.
-
-
-
-
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- Rekruttering
- Edinburgh Cancer Centre
-
Ledende efterforsker:
- Colin Barrie, MD
-
London, Det Forenede Kongerige, SM2 5PT
- Rekruttering
- The Royal Marsden - Chelsea
-
Ledende efterforsker:
- Sanjay Popat MD
-
Manchester, Det Forenede Kongerige, M20 4BX
- Rekruttering
- The Christie NHS Foundation Trust
-
Ledende efterforsker:
- Matthew Krebs, MB ChB PhD
-
-
Surrey
-
Sutton, Surrey, Det Forenede Kongerige, SM2 5PT
- Rekruttering
- Royal Marsden Hospital
-
Ledende efterforsker:
- Sanjay Popat MD
-
-
-
-
California
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- University of California Irvine Medical Center
-
Ledende efterforsker:
- Misako Nagasaka, MD
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- University of California, Davis Comprehensive Cancer Center
-
Ledende efterforsker:
- Jonathan Riess, MD
-
Stanford, California, Forenede Stater, 94305
- Rekruttering
- Stanford Cancer Institute
-
Ledende efterforsker:
- Joel Neal, MD, PhD
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado Cancer Center
-
Ledende efterforsker:
- Ross Camidge, MD, PhD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- Georgetown University Medical Center
-
Ledende efterforsker:
- Joshua Reuss, MD
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami; Sylvester Cancer Center
-
Ledende efterforsker:
- Gilberto de Lima Lopes, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute, Emory University
-
Ledende efterforsker:
- Ticiana Leal, MD
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Medical Center
-
Ledende efterforsker:
- Marina Garassino, MD
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21224
- Rekruttering
- John Hopkins University
-
Ledende efterforsker:
- Vincent Lam, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Ledende efterforsker:
- Jessica Lin, MD
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana Farber Cancer Institute
-
Ledende efterforsker:
- Alice Shaw, MD
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Cancer Institute
-
Ledende efterforsker:
- Bindu Potugari, MD
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63310
- Rekruttering
- Washington University School of Medicine Siteman Cancer Center
-
Ledende efterforsker:
- Saiama Waqar, MD
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Ledende efterforsker:
- Alexander Drilon, MD
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
Ledende efterforsker:
- Elaine Shum, MD
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke University Medical Center
-
Ledende efterforsker:
- Thomas Stinchcombe, MD
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- OSU Brain & Spine Hospital
-
Ledende efterforsker:
- Logan Roof, MD, MSCR
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania, Abramson Cancer Center
-
Ledende efterforsker:
- Charu Aggarwal, MD
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon
-
Ledende efterforsker:
- Melissa Johnson, MD
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Aktiv, ikke rekrutterende
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Ledende efterforsker:
- Christina Baik, MD, MPH
-
-
-
-
-
Lyon, Frankrig, 69373
- Rekruttering
- Centre Leon Berard
-
Ledende efterforsker:
- Aurelie Swalduz, MD
-
Nantes, Frankrig, 44093
- Rekruttering
- Chu De Nantes
-
Ledende efterforsker:
- Elvire Pons-Tostivint, MD, PhD
-
Toulouse, Frankrig, 31059
- Rekruttering
- Institut Claudius Regaud
-
Ledende efterforsker:
- Julien Mazieres, MD, PhD
-
Villejuif, Frankrig, 94805
- Rekruttering
- Institute Gustave Roussy
-
Ledende efterforsker:
- Benjamin Besse, MD, PhD
-
-
-
-
-
Amsterdam, Holland, 1066 CX
- Rekruttering
- The Netherlands Cancer Institute
-
Ledende efterforsker:
- Adrianus Joop de Langen, MD
-
Groningen, Holland, 9713 GZ
- Rekruttering
- University Medical Center Groningen (UMCG)
-
Ledende efterforsker:
- AJ Van Der Wekken, MD
-
-
-
-
-
Ancona, Italien, 60126
- Rekruttering
- Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto
-
Ledende efterforsker:
- Rossana Berardi, MD
-
Bari, Italien, 70124
- Rekruttering
- IRCCS Istituto Tumori "G. Paolo II"
-
Ledende efterforsker:
- Domenico Galetta, MD
-
Milan, Italien, 20133
- Rekruttering
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Ledende efterforsker:
- Sara Cresta, MD
-
Milan, Italien, 20141
- Rekruttering
- Instituto Europeo di Oncologia
-
Ledende efterforsker:
- Gianluca Spitaleri, MD
-
Padova, Italien, 35128
- Rekruttering
- Instituto Oncologico Veneto
-
Ledende efterforsker:
- Giulia Pasello, MD
-
Ravenna, Italien, 48100
- Rekruttering
- Ospedale Santa Maria delle Croci
-
Ledende efterforsker:
- Chiara Bennati, MD
-
Rome, Italien, 00144
- Rekruttering
- Regina Elena Institute for Cancer Research
-
Ledende efterforsker:
- Lorenza Landi, MD
-
-
-
-
-
Kanagawa, Japan, 2418515
- Rekruttering
- Kanagawa Cancer Center
-
Ledende efterforsker:
- Tetsuro Kondo, MD
-
Okayama, Japan, 7008558
- Rekruttering
- Okayama University Hospital
-
Ledende efterforsker:
- Kiichiro Ninomiya, MD
-
Osaka, Japan, 5898511
- Rekruttering
- Kindai University Hospital
-
Ledende efterforsker:
- Junko Tanizaki, MD
-
Shizuoka, Japan, 4118777
- Rekruttering
- Shizuoka Cancer Center
-
Ledende efterforsker:
- Ryo Ko, MD PhD
-
Tokyo, Japan, 1040051
- Rekruttering
- National Cancer Center Hospital
-
Ledende efterforsker:
- Tatsuya Yoshida, MD
-
Tokyo, Japan, 1358550
- Rekruttering
- Cancer Institute Hospital of JFCR
-
Ledende efterforsker:
- Ryo Ariyasu, MD
-
Wakayama, Japan, 6418510
- Rekruttering
- Wakayama Medical University Hospital
-
Ledende efterforsker:
- Hiroaki Akamatsu, MD, PhD
-
-
-
-
-
Bellinzona, Schweiz, 6500
- Rekruttering
- Istituto Oncologico Svizzera Italiana
-
Ledende efterforsker:
- Patrizia Froesch, MD
-
Lucerne, Schweiz, 6000
- Rekruttering
- Luzerner Kantonsspital
-
Ledende efterforsker:
- Anna Allemann, MD
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 119074
- Rekruttering
- National University Hospital
-
Ledende efterforsker:
- Ross Soo, MD
-
Singapore, Singapore, Singapore, 168583
- Rekruttering
- National Cancer Centre Singapore
-
Ledende efterforsker:
- Aaron Tan, MD
-
-
-
-
-
A Coruña, Spanien, 15006
- Rekruttering
- Complejo Hospitalario Universitario de A Coruna
-
Ledende efterforsker:
- Maria Campelo, MD
-
Barcelona, Spanien, 08035
- Rekruttering
- Vall d'Hebron
-
Ledende efterforsker:
- Enriqueta Felip, Md, PhD
-
Barcelona, Spanien, 08017
- Rekruttering
- UOMI Cancer Center
-
Ledende efterforsker:
- Santiago Viteri Ramirez, MD PhD
-
Madrid, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Ledende efterforsker:
- Luis Paz Ares, MD, PhD
-
Madrid, Spanien, 28009
- Rekruttering
- Hospital General Universitario Gregorio Maranon
-
Ledende efterforsker:
- Antonio Calles, MD
-
-
-
-
-
Seoul, Sydkorea, 03080
- Rekruttering
- Seoul National University Hospital
-
Ledende efterforsker:
- Dong-wan Kim, MD
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center
-
Ledende efterforsker:
- Myung-Ju Ahn, MD
-
Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital Yonsei University Health System
-
Ledende efterforsker:
- Byoung Chul Cho, MD
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Sydkorea, 10408
- Rekruttering
- National Cancer Center
-
Ledende efterforsker:
- Ji-Youn Han, MD
-
-
-
-
-
Taichung, Taiwan, 402306
- Rekruttering
- Chung-Shan Medical University Hospital
-
Ledende efterforsker:
- Gee-Chen Chang, MD
-
Tainan, Taiwan, 70403
- Rekruttering
- National Cheng Kung University Hospital
-
Ledende efterforsker:
- Chien-Chung Lin, MD
-
Taipei, Taiwan, 10002
- Rekruttering
- National Taiwan University Hospital
-
Ledende efterforsker:
- Josh Lin, MD
-
-
-
-
-
Cologne, Tyskland, 50937
- Rekruttering
- Universitatsklinikum Koln - University Hospital Cologne
-
Ledende efterforsker:
- Dr med Sebastian Michels
-
Frankfurt, Tyskland, 60590
- Rekruttering
- Universitätsklinikum Frankfurt
-
Ledende efterforsker:
- Martin Sebastian, MD
-
Großhansdorf, Tyskland, 22927
- Rekruttering
- LungenClinic Grosshansdorf GmbH
-
Ledende efterforsker:
- Prof Dr Martin Reck
-
Heidelberg, Tyskland, 69126
- Rekruttering
- Universkitatsklinikum Heidelberg - University Hospital Heidelberg
-
Ledende efterforsker:
- Prof Dr med Petros Christopoulos
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Age ≥18 years, Phase 2 Cohort 2f only: Age ≥12 years and weighing >40 kg. DDI sub-study Cohorts G and H only: age 18-60 years, inclusive
-
Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.
-
Phase 2
- Phase 2 Cohorts except 2f: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
- Phase 2 Cohort 2f: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation detected by certified assay.
-
DDI sub-study cohorts: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
-
DDI sub-study cohorts: Must have previously received ≥1 ALK TKI; no prior investigational agents targeting ALK; any number of prior chemotherapy and/or immunotherapy
-
Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1
-
Adequate organ function and bone marrow reserve
Exclusion criteria:
- Patient's cancer has a known oncogenic driver alteration other than ALK.
- Known allergy/hypersensitivity to excipients of NVL-655.
- Major surgery within 4 weeks of the study entry
- Ongoing or anticancer therapy
- Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Phase 1 dose escalation
Neladalkib (NVL-655) oral daily dosing |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2a
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received 1 prior 2nd-generation ALK TKI (ceritinib, alectinib, or brigatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2b
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received 2-3 prior ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib). Up to 2 prior lines of chemotherapy and/or immunotherapy are allowed. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2c
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who have received lorlatinib as the only prior ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy received prior to lorlatinib is allowed. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2d
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy. Up to one prior line of chemotherapy and/or immunotherapy is allowed. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2e
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort 2f
Patients with other solid tumors harboring an ALK rearrangement or activating ALK mutation, who have received ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists. |
Oral Tablet of Neladalkib (NVL-655) |
|
Eksperimentel: Cohort G (DDI sub-study)
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI |
Oral Tablet of Neladalkib (NVL-655) Oral Solution of Midazolam Oral Tablet of Repaglinide |
|
Eksperimentel: Cohort H (DDI sub-study)
Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement who have received ≥1 prior ALK TKI |
Oral Tablet of Neladalkib (NVL-655) Oral Solution of Itraconazole |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) (Phase 2)
Tidsramme: 2-3 years after first patient dosed.
|
To determine ORR as assessed by BICR |
2-3 years after first patient dosed.
|
|
Dose limiting toxicities (DLTs) (Phase 1)
Tidsramme: Within the first 21 days of the first neladalkib (NVL-655) dose
|
Define the dose limiting toxicities (DLTs) |
Within the first 21 days of the first neladalkib (NVL-655) dose
|
|
Recommended Phase 2 Dose (RP2D) (Phase 1)
Tidsramme: Within 21 days of last patient dosed during escalation
|
To determine the RP2D |
Within 21 days of last patient dosed during escalation
|
|
Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1)
Tidsramme: Approximately 3 years
|
Incidence and severity of treatment-emergent adverse events (TEAEs) |
Approximately 3 years
|
|
Area under the curve of repaglinide (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the effect of multiple oral doses of neladalkib (NVL-655) on the PK of a single oral dose of repaglinide |
Pre-dose and up to 24 hours post-dose
|
|
Area under the curve of midazolam (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the effect of multiple oral doses of neladalkib (NVL-655) on the PK of a single oral dose of midazolam |
Pre-dose and up to 24 hours post-dose
|
|
Area under the curve of neladalkib (NVL-655) (Phase 2 DDI sub-study)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the effect of itraconazole on the single oral dose PK of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum plasma concentration, (Cmax) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the maximum plasma concentration (Cmax) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Plasma concentration at the end of the dosing interval (Ctau) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the plasma concentration at the end of the dosing interval (Ctau) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Average plasma concentration (Cavg) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the average plasma concentration (Cavg) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Time of maximum concentration (Tmax) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the time of maximum concentration (Tmax) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Area under the curve at the end of the dosing interval (AUCtau) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the area under the curve at the end of the dosing interval (AUCtau) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Area under the curve from time 0 to 24 (AUC0-24) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the area under the curve from time 0 to 24 (AUC0-24) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Area under the curve from time 0 to infinity (AUCinf) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the area under the curve from time 0 to infinity (AUCinf) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Oral clearance (CL/F) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the oral clearance (CL/F) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Volume of distribution (Vz/F) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the volume of distribution (Vz/F) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Half-life (t1/2) of neladalkib (NVL-655)
Tidsramme: Pre-dose and up to 24 hours post-dose
|
To determine the half-life (t1/2) of neladalkib (NVL-655) |
Pre-dose and up to 24 hours post-dose
|
|
Objective response rate (ORR) (Phase 1)
Tidsramme: 2-3 years after first patient dosed
|
Determine ORR as assessed by Investigator |
2-3 years after first patient dosed
|
|
Duration of response (DOR)
Tidsramme: 2-3 years after first patient dosed
|
Determine DOR of neladalkib (NVL-655) until radiographic disease progression or death |
2-3 years after first patient dosed
|
|
Clinical benefit rate (CBR)
Tidsramme: 2-3 years after first patient dosed
|
Determine CBR of neladalkib (NVL-655) |
2-3 years after first patient dosed
|
|
Time to response
Tidsramme: Approximately 3 years
|
Determine time to response of neladalkib (NVL-655) |
Approximately 3 years
|
|
Progression-free survival (PFS)
Tidsramme: 2-3 years after first patient dosed
|
Determine PFS of neladalkib (NVL-655) until radiographic disease progression or death |
2-3 years after first patient dosed
|
|
Overall survival (OS) (Phase 2)
Tidsramme: Approximately 3 years
|
Determine OS |
Approximately 3 years
|
|
Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 2)
Tidsramme: Approximately 3 years
|
Incidence and severity of treatment-emergent adverse events (TEAEs) |
Approximately 3 years
|
|
Quality of life assessment
Tidsramme: 2-3 years after first patient dosed
|
Measure the quality of life in patients with cancer and/or lung cancer. |
2-3 years after first patient dosed
|
|
Incidence and severity of AEs and incidence of abnormalities across laboratory values, ECGs, vital signs, and physical examinations (Phase 2 DDI-sub-study)
Tidsramme: Up to 3 months after last dose
|
Assess the safety and tolerability of neladalkib (NVL-655) when co-administered with repaglinide or midazolam |
Up to 3 months after last dose
|
|
Incidence and severity of AEs and incidence of abnormalities across laboratory values, ECGs, vital signs, and physical examinations (Phase 2 DDI-sub-study)
Tidsramme: Up to 3 months after last dose
|
Assess the safety and tolerability of neladalkib (NVL-655) when co-administered with itraconazole |
Up to 3 months after last dose
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Viola Zhu, MD, PHD, Nuvalent Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Neoplastiske processer
- Patologiske tilstande, tegn og symptomer
- Neoplasma Metastase
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Azoler
- Benzazepiner
- Benzodiazepiner
- Triazoler
- Piperaziner
- Midazolam
- Itraconazol
- Repaglinide
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NVL-655-01
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .